Multiple sclerosis and related disorders最新文献

{"title":"Results from a multiple sclerosis relapse clinic","authors":"Ger Mullan ,&nbsp;Rachael Kee ,&nbsp;Fiona Kennedy ,&nbsp;Stella Hughes ,&nbsp;Gavin V McDonnell","doi":"10.1016/j.msard.2025.106459","DOIUrl":"10.1016/j.msard.2025.106459","url":null,"abstract":"<div><h3>Background</h3><div>A multiple sclerosis (MS) relapse clinic can lead to early diagnosis and management of MS relapses, yet published outcomes from MS relapse clinics are scarce.</div></div><div><h3>Methods</h3><div>We analysed the Belfast Health and Social Care Trust (BHSCT) relapse clinic over a 12 month period.</div></div><div><h3>Results</h3><div>Only 16 % of attendees were diagnosed with a relapse, defined as new neurological symptoms with radiological evidence of new disease activity. Pseudorelapse was a more common cause of presentation (19 %) than relapse. Corticosteroid therapy was administered in 3 % of all attendances.</div></div><div><h3>Conclusions</h3><div>This low figure highlights the importance of clinical evaluation of new symptoms, justifies caution in corticosteroid prescribing and may reflect the impact of highly-effective therapies. We encourage other groups to publish their relapse clinic findings to best characterise the frequency of relapses and the utility of such services using real world data.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106459"},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avoidance behavior mediates the relationship between concern about falling and impaired mobility in multiple sclerosis","authors":"Taylor N. Takla ,&nbsp;Patrick G. Monaghan ,&nbsp;Ana M. Daugherty ,&nbsp;Nora E. Fritz","doi":"10.1016/j.msard.2025.106462","DOIUrl":"10.1016/j.msard.2025.106462","url":null,"abstract":"<div><h3>Background</h3><div>Concern about falling (CAF) is common in multiple sclerosis (MS) and affects mobility and activity, even without a history of a falls.</div></div><div><h3>Objectives</h3><div>This study aimed to assess how avoidance behavior contributes to CAF-related mobility impairments and whether this association is consistent for fallers and non-fallers.</div></div><div><h3>Methods</h3><div>Participants completed questionnaires regarding CAF, avoidance behavior, and self-reported walking impairment, and laboratory walking and balance assessments. Applied structural equation modeling tested a hypothesized mediation model in which the relationship between CAF and mobility impairments would be partially mediated by avoidance behavior. Walking and balance assessments were used to construct a mobility latent factor. The model was subsequently stratified by fallers and non-fallers.</div></div><div><h3>Results</h3><div>Participants included 52 individuals with MS. 46.96 % of the significant total effect of CAF on mobility was accounted for by avoidance behaviors. No significant differences were found between fallers and non-fallers, suggesting a consistent mediation effect across both groups.</div></div><div><h3>Conclusions</h3><div>Our findings underscore the role of avoidance behavior in partially accounting for the effects of CAF on mobility deficits among persons with MS. This effect was statistically equivalent across fall status, highlighting the pervasive impact of avoidance behavior on mobility impairments in MS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106462"},"PeriodicalIF":2.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the synchronized telerehabilitation-based upper extremity training program on hand-arm functions in people with multiple sclerosis","authors":"Seda Dastan ,&nbsp;Özge Ertekin ,&nbsp;Asiye Tuba Ozdogar ,&nbsp;Turhan Kahraman ,&nbsp;Cavid Baba ,&nbsp;Serkan Ozakbas","doi":"10.1016/j.msard.2025.106438","DOIUrl":"10.1016/j.msard.2025.106438","url":null,"abstract":"<div><h3>Background</h3><div>Between 60 % and 75 % of people with MS (PwMS) report having upper extremity dysfunction. Synchronized telerehabilitation offers immediate feedback and personalized treatment beyond standard clinical services.</div></div><div><h3>Objectives</h3><div>To evaluate the effects of an 8-week synchronized telerehabilitation-based upper extremity training program on hand-arm function in PwMS and compare these effects with an asynchronous treatment group.</div></div><div><h3>Method</h3><div>The Synchronized group (<em>n</em>=12) received online upper extremity exercises twice a week from a physiotherapist. The Asynchronous group (<em>n</em>=13) performed the same exercises via instructional videos. All participants were assessed at baseline and after 8 weeks using the Nine-Hole Peg Test (N<img>HPT), JAMAR Hand Dynamometer, and the Arm Function Questionnaire for Multiple Sclerosis (AMSQ). Additionally, quality of life, fatigue, physical activity, participation, and pain were evaluated using various validated scales and questionnaires.</div></div><div><h3>Results</h3><div>The Synchronized group showed significant improvements in the N<img>HPT, JAMAR Hand Dynamometer scores, and the AMSQ after 8 weeks (<em>p</em>&lt;0.05). Specifically, the synchronized group demonstrated a marked reduction in the time to complete the N<img>HPT, indicating enhanced dexterity and coordination. The JAMAR Hand Dynamometer scores revealed substantial gains in grip strength, suggesting improved muscle function. Patient-reported outcomes from the AMSQ indicated better perceived upper extremity functionality. Furthermore, the synchronized group experienced a significant reduction in fatigue levels (<em>p</em>&lt;0.05) and an increase in quality of life and participation in daily activities (<em>p</em>&lt;0.05). However, both the synchronized and asynchronous groups did not show significant changes in pain levels (<em>p</em>&gt;0.05). The Asynchronous group also displayed improvements in upper extremity function, but these were less pronounced compared to the synchronized group.</div></div><div><h3>Conclusion</h3><div>The results show that synchronized-based telerehabilitation training performed with a physiotherapist is an effective method on hand-arm function. In addition, synchronized training seems to be effective on fatigue, quality of life and participation in PwMS,</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"98 ","pages":"Article 106438"},"PeriodicalIF":2.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal relationship between neurofilament light chain and cytokines involved in T helper-17 lymphocyte signaling in the blood of experimental autoimmune encephalomyelitis mice","authors":"Raveesh Koul ,&nbsp;Wei Lu ,&nbsp;Timothy Torres ,&nbsp;Yun-Beom Choi","doi":"10.1016/j.msard.2025.106463","DOIUrl":"10.1016/j.msard.2025.106463","url":null,"abstract":"<div><h3>Background</h3><div>Multiple sclerosis (MS) is an autoimmune neuroinflammatory disease leading to eventual neurodegeneration. There is a strong interest in using blood biomarkers to detect the disease onset and monitor disease progression in MS. One such biomarker is neurofilament light chain (NfL) that reflects axonal damage or neurodegeneration. Proinflammatory cytokines involved in T-helper 17 (Th17) lymphocyte signaling are potential blood biomarkers of neuroinflammation.</div></div><div><h3>Methods</h3><div>We induced experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, in female C57BL/6 mice and measured the progression of EAE using a clinical score. We collected blood from EAE mice on the post-immunization days 7, 10, 16, or 22 and measured NfL concentrations using single molecule array (SIMOA) technology. We also measured concentrations of cytokines related to Th17 using xMAP immune assay technology (Luminex) from the same mice.</div></div><div><h3>Results</h3><div>We found that the concentration of NfL began to rise at the onset of clinical symptoms on the post-immunization day 10 and peaked on day 16, closely correlating with the clinical score. However, the concentrations of several proinflammatory cytokines, including IFN-γ, IL-6, IL-17A, IL-22, and TNF-α, were already elevated even before the onset of the clinical symptoms and did not correlate positively with the clinical scores.</div></div><div><h3>Conclusion</h3><div>Our results confirmed the utility of NfL as a blood biomarker for disease progression in MS. The elevation of multiple proinflammatory cytokines concentrations in the blood of the same EAE mice in the presymptomatic stage suggested that blood biomarkers for neuroinflammation increased before blood biomarkers for neurodegeneration during the disease course in EAE.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106463"},"PeriodicalIF":2.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143863441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuromuscular electrical stimulation reduces spinal excitability in Multiple Sclerosis patients with spasticity symptoms","authors":"Martina Scalia ,&nbsp;Riccardo Borzuola ,&nbsp;Martina Parrella ,&nbsp;Giovanna Borriello ,&nbsp;Francesco Sica ,&nbsp;Fabrizia Monteleone ,&nbsp;Andrea Macaluso","doi":"10.1016/j.msard.2025.106457","DOIUrl":"10.1016/j.msard.2025.106457","url":null,"abstract":"<div><h3>Background</h3><div>The use of neuromuscular electrical stimulation (NMES) has been recently proposed in patients with neurological diseases, such as spinal cord injuries and stroke, to improve symptoms of spasticity, resulting in both increased control of voluntary movements and improved functional ability in daily activities. Despite several authors suggest that these results could be related to a reduced spinal excitability, which is known to be higher in spastic patients, no previous studies investigated the neurophysiological mechanisms underlying the effect of NMES in reducing spasticity. In addition, there are no studies in the literature adopting NMES to improve spasticity in patients with Multiple Sclerosis (MS). Therefore, this study aims at comparing acute responses in spinal excitability, as measured by H-reflex, between MS patients with and without spasticity, following three experimental conditions: 1) isometric voluntary contraction (ISO) of the ankle plantar flexor muscles; 2) NMES passively applied (pNMES) to the ankle plantar flexor muscles; and 3) NMES superimposed onto isometric voluntary contraction (NMES+) of the same muscles.</div></div><div><h3>Methods</h3><div>15 MS patients with spasticity (MS+) and 15 MS patients without spasticity (MS-) took part in a single experimental session, which consisted in the application of NMES to the ankle plantar-flexor muscles in the most spastic and compromised leg. Following the assessment of maximum voluntary isometric contraction (MVIC), participants were asked to perform 15 repetitions of 6 s at 20 % of MVIC, with 6 s of recovery between repetitions, during the three experimental conditions (ISO, pNMES, NMES+). Before and after each condition, soleus (SOL) H-reflex amplitudes were recorded by using surface electromyography (sEMG).</div></div><div><h3>Results</h3><div>In MS+, H-reflex amplitude significantly decreased after both pNMES (<em>p</em> = 0.007) and NMES+ (<em>p</em> = 0.003), while it was unaltered after ISO (<em>p</em> = 0.829). In MS-, H-reflex amplitude did not change under any experimental condition (ISO: <em>p</em> = 0.383; pNMES: <em>p</em> = 0.328; NMES+: <em>p</em> = 0.087).</div></div><div><h3>Conclusion</h3><div>The reduction of H-reflex after pNMES and NMES+ can be attributed to a reduced spinal excitability in spastic MS patients, which may be attributed to presynaptic inhibition, recurrent inhibition, gamma-aminobutyric acid activity and persistent inward current. These results are highly relevant from both neurophysiological and clinical point of views, suggesting new approaches to manage spasticity symptoms in neurological patients.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106457"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data","authors":"Benjamin M. Greenberg ,&nbsp;Kazuo Fujihara ,&nbsp;Brian Weinshenker ,&nbsp;Francesco Patti ,&nbsp;Ingo Kleiter ,&nbsp;Jeffrey L. Bennett ,&nbsp;Jacqueline Palace ,&nbsp;Kathleen Blondeau ,&nbsp;Alexander Burdeska ,&nbsp;Innocent Ngwa ,&nbsp;Gaëlle Klingelschmitt ,&nbsp;Miriam Triyatni ,&nbsp;Takashi Yamamura","doi":"10.1016/j.msard.2025.106444","DOIUrl":"10.1016/j.msard.2025.106444","url":null,"abstract":"<div><div>Satralizumab showed a comparable safety profile versus placebo in 2 pivotal neuromyelitis optica spectrum disorder (NMOSD) studies. We analyzed infection rates with long-term satralizumab treatment in the open-label study, SAkuraMoon, and in a post-marketing setting (PMS), comparing frequencies with US-based health claims real-world data (US-RWD).</div><div>Incidence rates of infection per 100 patient-years (IR/100 PY) were analyzed in the SAkura studies (clinical cut-off date: 31 January 2023). Reported rates of infection ( %) in a PMS using Periodic Benefit–Risk Evaluation Reports (2020–2023), and cumulative incidence of infections ( %) from the US PharMetrics claims data in NMOSD patients (2017–2022) were analyzed.</div><div>166 patients (SAkura studies), 2951 patients (PMS) and 2872 patients (US-RWD) were included. In the SAkura studies, the incidence rates of infection, serious infection, and sepsis were lower versus the double-blind period (IR/100 PY [95 % confidence intervals (Tur, C. et al.)] infection 91.7 [85.5–98.3] vs 113.0 [98.6–129.0]; serious infection 2.6 [1.7–3.9] vs 4.1 [1.8–8.1]; sepsis 0.6 [0.2–1.3] vs 1.0 [0.1–3.7], respectively). In a PMS, reported rates of infection, serious infection, and sepsis were 7.3 %, 3.8 %, and 0.6 %, respectively. In the US-RWD, cumulative incidence of infection, serious infection, and sepsis in NMOSD were 67.3 %, 8.4 %, and 4.9 %, respectively. Concomitant IST use, comorbidities, Expanded Disability Status Scale score ≥4.0, and age &gt;65 years were potential confounders of sepsis.</div><div>US-RWD indicated infection is a major comorbidity in NMOSD, independent of satralizumab treatment. Infection rates were consistently lower in satralizumab-treated patients compared with US-RWD.</div><div>Trial Registration: NCT04660539(SAkuraMoon), NCT02028884(SAkuraSky), NCT02073279(SAkuraStar).</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106444"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of dysarthria in the multiple sclerosis population: A systematic review and meta-analysis","authors":"Vassiliki Smyrni ,&nbsp;Vasileios Giannopapas ,&nbsp;Dimitrios K. Kitsos ,&nbsp;Konstantina Stavrogianni ,&nbsp;Athanasios K. Chasiotis ,&nbsp;Georgia Papagiannopoulou ,&nbsp;Alexandros S. Triantafyllou ,&nbsp;Pinelopi Vlotinou ,&nbsp;Georgios Tsivgoulis ,&nbsp;Anastasios Bonakis ,&nbsp;George P. Paraskevas ,&nbsp;Sotirios Giannopoulos","doi":"10.1016/j.msard.2025.106458","DOIUrl":"10.1016/j.msard.2025.106458","url":null,"abstract":"<div><h3>Introduction</h3><div>Dysarthria is a common type of motor speech disorder seen in people with MS (PwMS), with studies reporting a prevalence ranging from 40 % to 51 %. There is inconsistent evidence regarding its specific prevalence and its potential association with disability progression and disease duration.</div></div><div><h3>Methods</h3><div>This systematic review and meta-analysis aims to estimate the prevalence of dysarthria in PwMS and to explore potential associations between dysarthria and demographic and disease-specific factors. Adhering to PRISMA guidelines, a detailed search of the MEDLINE PubMed, Cochrane Library, and Scopus databases was conducted.</div></div><div><h3>Results</h3><div>A total of 14 studies involving 1833 MS patients were included, revealing a pooled prevalence of dysarthria in MS of 44.9 % (95 % CI [31.9,58.2], I2=96.2 %, <em>p</em> &lt; 0.00). The aggregated risk ratio of speech disorders in MS patients versus healthy controls was 8.09 (95 %CI [2.40, 27.26], pz=0.0007, I²=53 %, <em>p</em> = 0.05. However, meta-regression sensitivity analysis showed no statistically significant associations between speech disorders and age, or disability level but there was evidence of an anti proportional linear relationship between the prevalence of speech disorders and disease duration (<em>p</em> = 0.1)</div></div><div><h3>Conclusion</h3><div>This systematic review and meta-analysis found a 44.9 % prevalence of dysarthria in the MS population; however, no relationship could be established between dysarthria and demographic and disease-specific characteristics. Considering the impact of dysarthria in the quality of life in PwMS, as well as the diagnostic limitations currently existing in clinical practice, this study highlights the necessity for future studies to, systematically and accurately, record dysarthria symptomatology and aetiology in PwMS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"98 ","pages":"Article 106458"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incomparable regional prevalence estimates of Neuromyelitis Optica due to lack of standardization: Comment on the article by Taskiran et.al.","authors":"Alp Temiz ,&nbsp;Koray Tascilar","doi":"10.1016/j.msard.2025.106455","DOIUrl":"10.1016/j.msard.2025.106455","url":null,"abstract":"","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"98 ","pages":"Article 106455"},"PeriodicalIF":2.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcome of double-AQP4/MOG-seronegative and not MS-associated monophasic and relapsing demyelinating transverse myelitis: A monocenter study","authors":"Michael Auer ,&nbsp;Harald Hegen ,&nbsp;Franziska Di Pauli ,&nbsp;Gabriel Bsteh ,&nbsp;Anne Zinganell ,&nbsp;Klaus Berek ,&nbsp;Robert Barket ,&nbsp;Thomas Berger ,&nbsp;Florian Deisenhammer","doi":"10.1016/j.msard.2025.106454","DOIUrl":"10.1016/j.msard.2025.106454","url":null,"abstract":"<div><h3>Background</h3><div>Demyelinating acute transverse myelitis (ATM) may occur as part of the clinical presentation in multiple sclerosis (MS) as well as neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disease (MOGAD). However, some patients with demyelinating ATM do not fulfill diagnostic criteria of MS, NMOSD or MOGAD and some of these even experience more than one spinal relapse. As double-AQP4/MOG-seronegative demyelinating ATM (DSD-ATM) is poorly investigated so far and treatment recommendations for these patients are lacking, we aimed to investigate clinical features and outcome of these patients.</div></div><div><h3>Methods</h3><div>This is a retrospective chart-review study conducted at the Medical University of Innsbruck, using the Innsbruck MS database as well as medical charts to comprise a comprehensive cohort of people with DSD-ATM. We describe clinical and paraclinical characteristics as well as clinical outcome, comparing monophasic and relapsing DSD-ATM.</div></div><div><h3>Results</h3><div>Thirteen patients with relapsing and 19 with monophasic DSD-ATM were eligible for this study, of those 11 (34.4) female, with a mean age of 40.8 ± 15.5 years at first relapse and EDSS between 0 and 7.5 at last follow-up. While there was no difference in clinical outcome between these two groups, motor symptoms (<em>p</em> = 0.042, <em>Z</em> = -2.032) and higher age at first relapse (<em>p</em> = 0.024, ρ = 0.399) were predictors for poor outcome. No demographical or clinical variable, including magnetic resonance imaging and cerebrospinal fluid findings, was able to predict whether patients relapse or not after the first attack of ATM.</div></div><div><h3>Conclusion</h3><div>DSD-ATM is a rare and heterogenic entity of demyelinating disorders which may result in a relapsing disease course. Prediction of outcome and, thus, treatment choice remain challenging, requiring further studies.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106454"},"PeriodicalIF":2.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A supplementary training program integrating cold exposure, breathing exercises and mindfulness as a complementary treatment for neuropsychological aspects of multiple sclerosis – a pilot interventional study","authors":"Darina Slezáková ,&nbsp;Louise Mária Adamová ,&nbsp;Peter Marček ,&nbsp;Pavol Kadlic ,&nbsp;Michaela Konečná ,&nbsp;Peter Valkovič ,&nbsp;Michal Minár","doi":"10.1016/j.msard.2025.106450","DOIUrl":"10.1016/j.msard.2025.106450","url":null,"abstract":"<div><h3>Background</h3><div>Most of the patients with multiple sclerosis (MS) suffer from cognitive impairment, fatigue and/or mood disturbances. These symptoms are usually resistant to both disease-modifying and symptomatic treatment. Since there is a trend to a holistic approach to MS patients, we aimed to confirm the effect of combined cold exposure, controlled breathing and mindfulness - Wim Hof Method (WHM) – on neuropsychiatric symptoms of MS.</div></div><div><h3>Methods</h3><div>In this randomized interventional study we examined the change in the score of specific neuropsychiatric scales/questionnaires before and after the 12-week WHM-based training program. We compared the change with a control group with no intervention.</div></div><div><h3>Results</h3><div>We obtained complete data from 12 patients in the WHM group and 13 patients in the control group. After 12 weeks, the WHM group had significantly higher improvement in cognition - SDMT (<em>p</em> = 0.045), TMT-A (<em>p</em> = 0.041), TMT-B (<em>p</em> &lt; 0.001); fatigue - FSMC<img>C (<em>p</em> = 0.039); anxiety - GAD (<em>p</em> = 0.015), and depression - PHQ-9 (<em>p</em> = 0.033).</div></div><div><h3>Conclusion</h3><div>Our results indicate that the Wim Hof method appears to be a suitable complementary non-pharmacological treatment for neuropsychiatric symptoms of MS.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"99 ","pages":"Article 106450"},"PeriodicalIF":2.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}